Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer liver cancer drug gets orphan status from FDA

Bayer liver cancer drug gets orphan status from FDA

27th April 2006

Bayer Pharmaceuticals has announced its Nexavar liver cancer drug has been granted orphan status by the FDA, meaning Bayer will have exclusive right to market the product in the US despite the drug’s unpatentable nature. The European Commission has already granted Nexavar orphan status earlier this month.

Phase II trials indicated that 43 per cent of patients treated with Nexavar displayed the cancer becoming stable for four months, with nine per cent showing shrinkage in their tumours. Reported possible side effects included fatigue, diarrhoea and skin reactions on the hands and feet. Phase III trials are still ongoing for the use of Nexavar as a single agent. It is also being studied for use on skin cancer and non-small cell lung cancer.
Dr Jordi Bruix, head of the Barcelona clinic liver cancer group at the University of Barcelona, said: “Liver cancer is such an aggressive disease that patients diagnosed with it rarely live beyond two years.”

He added: “The global medical community recognises the need for new treatments in liver cancer and I am hopeful of the potential of Nexavar in this patient population.”

Bayer employs 2,500 people in the UK, where ten per cent of its shares are owned. Last year the German-based company experienced sales growth of 18 per cent, up to 27.4 billion euros (19.1 billion pounds).

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.